Phase 2Completed
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD)
A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer
- Sponsor
- Bristol-Myers Squibb (Industry)
- Enrollment
- 292 enrolled
- Conditions
- Prostate Cancer
- Interventions
- nivolumab; docetaxel; enzalutamide; rucaparib; prednisone
- Ages
- adults, older adults
- Registry
- NCT03338790
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to assess safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.
Primary outcomes
- Objective Response Rate Per Prostate Cancer Clinical Trials Working Group 3 (ORR-PCWG3)
- Prostate-Specific Antigen Response Rate (RR-PSA)
History
Last registry update
Study completion
Results first posted
Primary completion
Started
Registered